Myocardial Infarction - Pipeline Review, H2 2017

Date: September 12, 2017
Pages: 289
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MD027BAF1AAEN
Leaflet:

Download PDF Leaflet

Myocardial Infarction - Pipeline Review, H2 2017
Myocardial Infarction - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H2 2017, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 11, 11, 45, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 20 and 7 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Myocardial Infarction - Overview
Myocardial Infarction - Therapeutics Development
Myocardial Infarction - Therapeutics Assessment
Myocardial Infarction - Companies Involved in Therapeutics Development
Myocardial Infarction - Drug Profiles
Myocardial Infarction - Dormant Projects
Myocardial Infarction - Discontinued Products
Myocardial Infarction - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Myocardial Infarction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Myocardial Infarction - Pipeline by AstraZeneca Plc, H2 2017
Myocardial Infarction - Pipeline by Athersys Inc, H2 2017
Myocardial Infarction - Pipeline by Bayer AG, H2 2017
Myocardial Infarction - Pipeline by Bharat Biotech International Ltd, H2 2017
Myocardial Infarction - Pipeline by BioCardia Inc, H2 2017
Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by C&C BioPharma LLC, H2 2017
Myocardial Infarction - Pipeline by Cadila Healthcare Ltd, H2 2017
Myocardial Infarction - Pipeline by CellProthera, H2 2017
Myocardial Infarction - Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by Cynata Therapeutics Ltd, H2 2017
Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by FibroGen Inc, H2 2017
Myocardial Infarction - Pipeline by Hemostemix Ltd, H2 2017
Myocardial Infarction - Pipeline by Human Stem Cells Institute, H2 2017
Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H2 2017
Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by Juventas Therapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by K-Stemcell Co Ltd, H2 2017
Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H2 2017
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
Myocardial Infarction - Pipeline by LG Chem, Ltd., H2 2017
Myocardial Infarction - Pipeline by Lonestar Heart Inc, H2 2017
Myocardial Infarction - Pipeline by Mesoblast Ltd, H2 2017
Myocardial Infarction - Pipeline by miRagen Therapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by Moderna Therapeutics Inc, H2 2017
Myocardial Infarction - Pipeline by Navya Biologicals Pvt Ltd, H2 2017
Myocardial Infarction - Pipeline by New World Laboratories Inc, H2 2017
Myocardial Infarction - Pipeline by Novartis AG, H2 2017
Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H2 2017
Myocardial Infarction - Pipeline by Omeros Corp, H2 2017
Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H2 2017
Myocardial Infarction - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Myocardial Infarction - Pipeline by Prolong Pharmaceuticals LLC, H2 2017
Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by Reata Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by Recardio GmbH, H2 2017
Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017
Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H2 2017
Myocardial Infarction - Pipeline by Serodus ASA, H2 2017
Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H2 2017
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H2 2017
Myocardial Infarction - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
Myocardial Infarction - Pipeline by TiGenix NV, H2 2017
Myocardial Infarction - Pipeline by Vicore Pharma AB, H2 2017
Myocardial Infarction - Pipeline by XBiotech Inc, H2 2017
Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H2 2017
Myocardial Infarction - Dormant Projects, H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..1), H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..2), H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..3), H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..4), H2 2017
Myocardial Infarction - Dormant Projects, H2 2017 (Contd..5), H2 2017
Myocardial Infarction - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Myocardial Infarction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Amarantus Bioscience Holdings Inc
AstraZeneca Plc
Athersys Inc
Bayer AG
Bharat Biotech International Ltd
BioCardia Inc
Biscayne Pharmaceuticals Inc
C&C BioPharma LLC
Cadila Healthcare Ltd
CellProthera
Chrysalis BioTherapeutics Inc
Cynata Therapeutics Ltd
Diffusion Pharmaceuticals Inc
FibroGen Inc
Hemostemix Ltd
Human Stem Cells Institute
HUYA Bioscience International LLC
InCarda Therapeutics Inc
Juventas Therapeutics Inc
K-Stemcell Co Ltd
Laboratoires Pierre Fabre SA
Lee's Pharmaceutical Holdings Ltd
LG Chem, Ltd.
Lonestar Heart Inc
Mesoblast Ltd
miRagen Therapeutics Inc
Moderna Therapeutics Inc
Navya Biologicals Pvt Ltd
New World Laboratories Inc
Novartis AG
NuvOx Pharma LLC
Omeros Corp
Opsona Therapeutics Ltd
Otsuka Holdings Co Ltd
Prolong Pharmaceuticals LLC
Quark Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Recardio GmbH
RegeneRx Biopharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Rubicon Biotechnology Inc
Serodus ASA
Silver Creek Pharmaceuticals Inc
TaiGen Biotechnology Co Ltd
Tasly Pharmaceutical Group Co Ltd
TiGenix NV
Vicore Pharma AB
XBiotech Inc
Yuyu Pharma Inc
Skip to top


Myocardial Ischemia - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 84 pages
Myocardial Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Dec, 2016 · 65 pages
Myocardial Fibrosis - Pipeline Review, H1 2017 US$ 2,000.00 Jun, 2017 · 68 pages

Ask Your Question

Myocardial Infarction - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: